Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Texas Has Given Birth to Its First and Only Global Publicly Traded Cannabis Company, Cannabis Bioscience International Holdings

CBIH

This Calls for a Celebration

Houston, Texas--(Newsfile Corp. - December 15, 2023) - On December 5, 2023, Cannabis Bioscience International Holdings (OTC Pink: CBIH) , a Houston, TX, based company, trading on the OTC Markets under the ticker symbol CBIH, announced that its registration statement on Form S-1 (File No. 333-267039), filed under the Securities Act of 1933, was declared effective by the United States Securities and Exchange Commission (the "SEC").

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10188/191172_cbih1.jpg

Cannabis Bioscience International Holdings

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10188/191172_cbih1en.jpg

A large part of the credit for this accomplishment goes to the people of Texas who have supported our journey to advance. "Texans' hard work, perseverance and healthy disregard for the impossible have undoubtedly paid off," said Dr. Jose Torres, MD, CBIH International Medical Director.

The company is dedicated to providing services in all therapeutic areas of clinical research offering phase II to phase IV Clinical Research Studies, and has worked with different companies including BioIVT, Phillips Morris, Pfizer, and Inventiva, among many others.

However, the company intends to invest in its very own future and plans to use the proceeds from its offering to start its own cannabis clinical trials using AI programs to optimize the research processes. Thus, acquiring clinical evidence of how its 15 years of intellectual property cannabinoid formulations can aid in the treatment of cancer, PTSD, COVID-19, Herpes Zoster (shingles), chronic pain, among other conditions. "Clinical research is the cornerstone of medicinal treatments and the ultimate push for patients to consider cannabinoid therapies their first option, not their last resource," said Henry Levinski, CBIH Treasurer and VP.

Certainly, CBIH will keep innovating to represent Texas as leaders and pioneers in the medicinal cannabis industry on the front line of scientific cannabinoid research. Meanwhile, with the granted SEC effectiveness of the company, Texas can be proud to have made it into the elite space of publicly traded companies.

For more information contact us at:

(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/191172